CDC Website CDC Website

To Join the NPIN community or

Home » Tuberculosis Elimination and Laboratory Cooperative Agreement

Tuberculosis Elimination and Laboratory Cooperative Agreement

This NOFO supports the continued focus on identifying and curing persons with TB disease, but also includes the addition of a targeted testing and treatment strategy for LTBI. TB disproportionately affects certain populations, including those who are non-U.S.-born, with HIV infection or diabetes, experiencing homelessness, who are incarcerated, and who use illicit substances. The TB incidence rate among non-U.S.-born persons in 2017 was approximately 15 times greater compared to U.S.-born persons, and the percentage of TB cases occurring in non-U.S.-born persons continues to increase, reaching 70.1% in 2017. Achieving TB elimination in the United States will require focusing on persons in these high-risk groups – an approach that is reinforced by this NOFO. CDC is continuing a 30-year strategy of funding TB programs through cooperative agreements (CoAgs). The primary responsibility for developing and implementing TB P&C and laboratory activities rests with state and local health departments, and this funding is intended to complement those efforts. The intent of this funding is not to supplant or reduce state and local investment in TB control activities and responsibilities (e.g., provision of medications, in-patient care, and health department facilities). 

Funding Category
Locations
National
Eligible Organizations
Number of Awards Given
61 awards.
Application Due Date
9/5/19
Award Date
12/1/19
Application Contact
Louvern
Asante
Grants Management Specialist
2939 Flowers Rd.
MS: TV2
Atlanta
30341
United States
GA
770-488-2835
LHA5@cdc.gov
Technical Contact
Glenroy
Christie
Project Office
1600 Clifton Road, NE
Atlanta
30333
GA
GPC5@cdc.gov
United States
404-639-8133
Fund Duration
Five years.
Subjects
Audiences
Focus Area

Fund Number: 

5489

Fund ID: 

CDC-RFA-PS20-2001

Last modified: 

8/26/19